Xeris Biopharma Holdings
XERS
92 hedge funds and large institutions have $80.6M invested in Xeris Biopharma Holdings in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 24 reducing their positions, and 13 closing their positions.
980% more call options, than puts
Call options by funds: $659K | Put options by funds: $61K
13% more capital invested
Capital invested by funds: $71.6M → $80.6M (+$8.99M)
13% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 24
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3.58% less ownership
Funds ownership: 39.61% → 36.03% (-3.6%)
4% less funds holding
Funds holding: 96 → 92 (-4)
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$841K |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$534K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$396K |
| 4 |
DAM
Deltec Asset Management
New York
|
+$317K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$304K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$4.32M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$3.2M |
| 3 |
Millennium Management
New York
|
-$923K |
| 4 |
BlackRock
New York
|
-$204K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$125K |
XERS Hedge Fund Activity: Q1 2023 in Review
92 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q1 2023, worth a combined $80.6M — up 13% from $71.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of XERS and 9 opened new positions — a net loss of 4 holders — while 24 trimmed existing stakes and 27 added.
The largest buyer was JP Morgan Chase, adding an estimated $841K. The largest seller was NEA Management Company, exiting entirely with an estimated $4.32M sold.
- 92 institutional investors held Xeris Biopharma Holdings (XERS) as of Q1 2023, down from 96 in Q4 2022.
- Funds reported $80.6M of Xeris Biopharma Holdings stock for Q1 2023, up 13% quarter-over-quarter.
- 9 funds opened new Xeris Biopharma Holdings positions in Q1 2023 and 13 closed out, a net change of -4 holders.
- The largest Xeris Biopharma Holdings buyer in Q1 2023 was JP Morgan Chase, an estimated $841K added.
- The largest Xeris Biopharma Holdings seller in Q1 2023 was NEA Management Company, an estimated $4.32M sold.
Based on aggregated 13F filings for Q1 2023.